Greenwich LifeSciences Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Greenwich LifeSciences, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue0.000.000.000.000.00
Cost of Revenue0.000.000.000.000.00
Gross Profit0.000.000.000.000.00
Operating Expenses
Research & Development12.957.706.483.561.06
Selling, General & Administrative3.061.631.561.040.81
Operating Expenses16.019.338.044.601.86
Operating Income-16.01-9.33-8.04-4.60-1.86
Other Income/Expense
Interest Income0.220.440.220.030.00
Interest Expense0.000.000.000.000.00
Other Income/Expense0.220.000.000.000.00
Income
Income Before Tax-15.79-8.89-7.83-4.57-1.86
Income Tax Expense0.000.000.000.000.00
Net Income-15.79-8.89-7.83-4.57-1.86
Net Income - Continuous Operations-15.79-8.89-7.83-4.570.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-16.01-9.32-8.04-4.59-1.86
EBIT-16.01-9.33-8.04-4.60-1.86
Depreciation & Amortization0.000.000.000.000.00
Earnings Per Share
Basic EPS-1.00-1.00-1.00--
Diluted EPS-1.00-1.00-1.00--
Basic Shares Outstanding13.0112.8512.9112.949.50
Diluted Shares Outstanding13.0112.8512.9112.949.50